<DOC>
	<DOC>NCT01418430</DOC>
	<brief_summary>The purpose of this study is to determine the safety of the combination of CHOP plus daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.</brief_summary>
	<brief_title>Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1. Histologically confirmed ATLL requiring treatment 1. Frank acute leukaemia or lymphoma subtypes 2. Chronic and smouldering cases should be considered if they are symptomatic and require therapy, or there is evidence of disease progression 2. No previous treatment with anthracycline based cytotoxic chemotherapy a. Patients may have received interferon and /or zidovudine and/or nonanthracycline based therapy 3. Age 1875 years 4. Written informed consent 1. HIV 1 or 2 positivity 2. Pregnancy or breastfeeding 3. Concomitant chemoradiotherapy 4. Prior hepatic or renal insufficiency with a bilirubin or transaminases greater than 5 times the normal range or a creatinine greater than 150Î¼mol/l (not related to hypercalcaemia) following rehydration 5. Other concomitant neoplasms not related to HTLVI 6. Cardiac or respiratory insufficiency with an ECOG score of greater than 3 7. Any serious active uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>